Phase I clinical trial in healthy adult  Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector)  COVID‐19  108, all, 18–60  Treatment  (Adenovirus Type 5 Vector)
Experimental: low‐dose group
Subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old  I  Primary (0–7 days postvaccination):
Safety indexes of adverse reactions
Secondary (0–28 days postvaccination, within 6 mouths postvaccination):
Safety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)
Other (Day 14,28, Month 6 postvaccination):
Consistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination)  NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021